New research indicates two doses of the vaccine boosts immunity from 74 to 94 percent
TUESDAY, Sept. 21, 2021 (HealthDay News) — Getting a second dose of the Johnson & Johnson COVID-19 vaccine substantially increased its protection, the company announced Tuesday.
According to the results of a new clinical trial, two doses of the vaccine boost immunity to 94 percent from the 74 percent offered by a single dose, the company said in a statement.
“Our single-shot vaccine generates strong immune responses and long-lasting immune memory. And, when a booster of the Johnson & Johnson COVID-19 vaccine is given, the strength of protection against COVID-19 further increases,” Mathai Mammen, M.D., Ph.D., global head of Janssen Research and Development at Johnson & Johnson, said in the statement.
Two shots are also 100 percent effective against a severe bout of disease, the company claimed. But that estimate is not certain, The New York Times reported.
The new data have been submitted to the U.S. Food and Drug Administration. Since the single-dose Johnson & Johnson vaccine was approved in February, nearly 15 million Americans have gotten it, The Times said.
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season
Trends Reported in Vaccination Coverage for Adolescents for 2025
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens
Social Media Warnings Could Discourage Use Among Teens, Young Adults
Digital Behavioral Health Game Reduces Depressive Symptoms in Teens
Flu Treatment With Oseltamivir Linked to Reduced Risk for Pediatric ICU Admissions, Length of Stay
Reinitiating Obesity Meds After Bariatric Surgery Tied to Greater One-Year Weight Loss in Youths